Examples of 'lumiracoxib' in a sentence
Meaning of "lumiracoxib"
lumiracoxib (noun): A nonsteroidal anti-inflammatory drug (NSAID) that belongs to the coxib class
Show more definitions
- A nonsteroidal anti-inflammatory drug, an analogue of diclofenac.
How to use "lumiracoxib" in a sentence
Basic
Advanced
lumiracoxib
Known hypersensitivity to lumiracoxib or to any of the excipients.
Lumiracoxib is excreted in the milk of lactating rats.
Omeprazole had no effect on the pharmacokinetics of lumiracoxib.
Lumiracoxib is eliminated predominantly via hepatic metabolism.
It is not known whether lumiracoxib is excreted in human milk.
Lumiracoxib crosses the placenta in rats and rabbits.
Manufacturers of celecoxib and lumiracoxib provided additional data.
Recommended follow up measures to further investigate the safety of lumiracoxib.
Women who use lumiracoxib should not breastfeed.
There were no significant differences between lumiracoxib and NSAIDs.
The pharmacokinetics of lumiracoxib in paediatric patients have not been studied.
It is advisable to rehydrate patients prior to starting therapy with lumiracoxib.
Lumiracoxib has demonstrated a gastrointestinal advantage compared with high doses of NSAIDs.
There is no difference in exposure of lumiracoxib in men and women.
The effect of lumiracoxib on the PK of other drugs Warfarin.
See also
Joicela is a medicine that contains the active substance lumiracoxib.
Particularly useful compounds of this class are lumiracoxib and pharmaceutically acceptable salts thereof.
Effects of other drugs on the PK of lumiracoxib.
In humans, lumiracoxib undergoes extensive hepatic metabolism.
Dialysis has no effect on the exposure of patients to lumiracoxib or its active metabolite.
Lumiracoxib can be used with low-dose aspirin.
Caution should be used when initiating treatment with lumiracoxib in patients with dehydration.
To develop and disseminate a Physician Decision Treatment Guide for prescribers of lumiracoxib.
Lumiracoxib and etoricoxib emerged as the second generation of CoxibsTable 1.
Toxicology Studies were conducted to elucidate the potential toxicity of lumiracoxib.
In preclinical studies, lumiracoxib has been demonstrated to be neither mutagenic nor carcinogenic.
Only about 5 % of the administered dose was recovered in excreta as unchanged lumiracoxib.
The cardiovascular safety of lumiracoxib beyond 1 year of use has not been established.
Aluminium hydroxide / magnesium hydroxide had no clinically relevant effect on the pharmacokinetics of lumiracoxib.
As with other NSAIDs, lumiracoxib may mask fever and other signs of inflammation or infection.
Of the total drug related material in plasma, unchanged lumiracoxib is the major component.
This indicates lumiracoxib and / or its metabolites are preferentially distributed and retained in inflamed tissue.
Overall summary of the scientific evaluation of medicinal products containing lumiracoxib ( see annex i ).
The data on lumiracoxib in the Target study, which suggested a small increase in.
Of the total drug-related material in plasma, unchanged lumiracoxib is the major component.
In vivo studies suggest that lumiracoxib has low potential for interactions with CYP2C9 substrates.
Serious hypersensitivity reactions ( such as anaphylaxis and angioedema ) have been reported in patients receiving lumiracoxib.
Breast-feeding mothers It is not known whether lumiracoxib is excreted in human milk.
The pharmacokinetics of lumiracoxib have not been studied in patients with severe hepatic impairment Child-Pugh > 9.
Gender, There is no difference in exposure of lumiracoxib in men and women.
The pharmacokinetics of lumiracoxib are similar in Asians, Blacks and Caucasians.
Is of the Opinion that the benefit / risk balance of medicinal products containing lumiracoxib in.
Paediatric patients: The pharmacokinetics of lumiracoxib in paediatric patients have not been studied.
Lumiracoxib is a COX-2 selective inhibitor nonsteroidal anti-inflammatory drug.
Effects of other drugs on the PK of lumiracoxib Fluconazole,.
Lumiracoxib ( Prexige ) is currently being considered.
The absolute bioavailability of lumiracoxib is approximately 74.
Chromosome aberrations were induced in V79 cells at high, cytotoxic concentrations of lumiracoxib.
The mean plasma half-life of lumiracoxib is approximately 4 hours.
Examples of NSAIDs also include COX-2 specific inhibitors such as celecoxib, valdecoxib, lumiracoxib dnd / or etoricoxib.
